Hookworm Infections
13
1
1
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
31%
4 trials in Phase 3/4
70%
7 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (13)
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Efficacy and Safety of MOX/ALB Co-administration
Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education
Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma